Stockscreener 앱 받기
39.64
2.61%
1.01
시간 외 거래:
39.64
전일 마감가:
$38.63
열려 있는:
$38.64
하루 거래량:
439.09K
Relative Volume:
2.05
시가총액:
$793.25M
수익:
$925.00K
순이익/손실:
$-98.64M
주가수익비율:
-7.8978
EPS:
-5.0191
순현금흐름:
$-83.37M
1주 성능:
+8.07%
1개월 성능:
+13.58%
6개월 성능:
+109.74%
1년 성능:
+98.30%
1일 변동 폭
$37.50
$40.82
1주일 범위
$35.21
$40.82
52주 변동 폭
$15.93
$43.66
Neurogene Inc Stock (NGNE) Company Profile
명칭
Neurogene Inc
전화
(877) 237-5020
주소
535 W 24TH STREET, NEW YORK
Compare NGNE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
39.64 | 760.23M | 925.00K | -98.64M | -83.37M | -5.0191 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Craig Hallum | Buy |
| 2025-05-16 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-29 | 개시 | Leerink Partners | Outperform |
| 2024-03-21 | 개시 | William Blair | Outperform |
| 2024-01-08 | 개시 | H.C. Wainwright | Buy |
| 2024-01-05 | 개시 | Stifel | Buy |
| 2024-01-04 | 개시 | TD Cowen | Outperform |
모두보기
Neurogene Inc 주식(NGNE)의 최신 뉴스
Balyasny Asset Management L.P. Expands Neurogene Inc (NGNE) Stak - GuruFocus
Neurogene (NGNE) Latest Quarter: Profit Per Share Falls Below Its Benchmark in Latest Trading; Market Response: Shares Finish 10.54% Higher in the Current UpdateFull Year Guidance - vinanet.vn
Neurogene (NGNE) Results at a Glance: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Response: Shares Rise 10.54% for the Current SessionGuidance Upgrade Report - vinanet.vn
Neurogene gearing up to apply for approval of Rett gene therapy - Rett Syndrome News
symbol__ Stock Quote Price and Forecast - CNN
NGNE Q1 2026 Earnings: Narrow EPS Miss Masks Positive Investor SentimentEarnings Forecast Report - vinanet.vn
Neurogene (NGNE) Gains 1.43% to $36.14: Key Resistance at $37.95 in FocusMoney Flow Index - vinanet.vn
Neurogene Inc. $NGNE Shares Bought by Renaissance Technologies LLC - MarketBeat
Neurogene Inc. (NGNE): Redmile Group and Jeremy Green disclose 9.9% stake - Stock Titan
Neurogene (NGNE) filers disclose 714,885-share Trails Edge stake at 4.5% - Stock Titan
Q3 Earnings Forecast for Neurogene Issued By HC Wainwright - marketbeat.com
Balyasny Asset Management (NGNE) discloses 5.18% Neurogene stake via Atlas fund - Stock Titan
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $63 to $166 - Moomoo
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF) - The Globe and Mail
Neurogene (NASDAQ:NGNE) Given New $166.00 Price Target at Canaccord Genuity Group - MarketBeat
Neurogene Maintained at Buy as Rett Program Progress and Strong Cash Runway Offset Price Target Trim from $180 to $166 - TipRanks
Neurogene (NGNE) Dips 2% to $35.8: Gene Therapy Developer Holds Above Key SupportSector Neutral Pair - Vinanet
Neurogene stock price target lowered to $65 by H.C. Wainwright - Investing.com
Canaccord lowers Neurogene stock price target on valuation review By Investing.com - Investing.com Nigeria
HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock Price - marketbeat.com
Canaccord lowers Neurogene stock price target on valuation review - Investing.com
William Blair Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
LifeSci Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $63 - Moomoo
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating - Moomoo
Neurogene Inc. Stock 12‑Month Price Target Cut to $79.75, Implies 118% Upside - TradingView
Neurogene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Neurogene Inc. Stock 12‑Month Price Target Cut to $78.5, Implies 115% Upside - TradingView
NEUROGENE INC : CANACCORD GENUITY CUTS TARGET PRICE TO $166 FROM $180 - Bitget
Neurogene Q2 Results: EPS widens to $(1.53), misses estimates - scanx.trade
Neurogene (NASDAQ:NGNE) Stock Price Down 7.8% on Disappointing Earnings - MarketBeat
Neurogene (NASDAQ:NGNE) Posts Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029 - TipRanks
Form 8K Neurogene Inc For: 11 August By Investing.com - Investing.com Nigeria
Neurogene publishes corporate presentation highlighting NGN-401 gene therapy program for Rett syndrome - Bitget
Neurogene Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neurogene: Q2 Earnings Snapshot - AOL.com
Neurogene Reports Q2 Net Loss of $34.5 Million - Quiver Quantitative
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates - marketscreener.com
NGNE Q1 2026 Earnings: Wider-than-Expected Loss Highlights R&D Investment, Shares Gain 2.41%ROIC Trend Report - vinanet.vn
Neurogene Inc (NGNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Neurogene Inc expected to post a loss of $1.42 a shareEarnings Preview - TradingView
Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of "Buy" from Analysts - MarketBeat
Neurogene (NASDAQ:NGNE): What Should Readers Watch Around Friday’s New Company Catalyst? - Kalkine Media
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
NGNE|Neurogene Inc|Price:34.380|Chg%:+1.510 - TradingKey
Neurogene (NGNE) Pulls Back 2.1% to $32.89 as Gene Therapy Stock Holds Above Critical SupportETH Profile - vinanet.vn
NGNE Q1 2026 Earnings: Wider-than-Expected Loss Dents SharesEstimate Revision Count - Vinanet
Neurogene Inc. Revenue Breakdown – NASDAQ:NGNE - TradingView
NGNE Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Neurogene Inc (NGNE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neurogene Inc 주식 (NGNE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cvijic Christine Mikail | President and CFO |
Jul 06 '26 |
Sale |
36.02 |
600 |
21,613 |
88,240 |
| Cvijic Christine Mikail | President and CFO |
Jul 02 '26 |
Sale |
34.82 |
4,061 |
141,417 |
88,840 |
| Cvijic Christine Mikail | President and CFO |
Jul 01 '26 |
Sale |
34.06 |
739 |
25,170 |
92,901 |
| Cvijic Christine Mikail | President and CFO |
May 06 '26 |
Sale |
31.25 |
9,600 |
300,043 |
93,640 |
0.00%
3.22%
자본화:
|
볼륨(24시간):